Emerging biomarkers in metastatic urothelial carcinoma: tumour mutational burden, PD-L1 expression and APOBEC polypeptide-like signature in a patient with complete response to anti-programmed cell death protein-1 inhibitor

Immunotherapy has recently been incorporated into the treatment guidelines for metastatic urothelial carcinoma. Nevertheless, the role of prognostic and predictive biomarkers in this setting is not completely defined. To date, PD-L1 expression and a high tumour mutational burden (TMB) seem to predic...

Descripción completa

Detalles Bibliográficos
Autores principales: Queiroz, Marcello Moro, de Souza, Zenaide Silva, Gongora, Aline Bobato Lara, de Galiza Barbosa, Felipe, Buchpiguel, Carlos Alberto, de Castro, Marilia Germanos, de Macedo, Mariana Petaccia, Coelho, Rafael Ferreira, Sokol, Ethan Samuel, Camargo, Anamaria Aranha, Bastos, Diogo Assed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580725/
https://www.ncbi.nlm.nih.gov/pubmed/34824629
http://dx.doi.org/10.3332/ecancer.2021.1306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580725/
https://www.ncbi.nlm.nih.gov/pubmed/34824629
http://dx.doi.org/10.3332/ecancer.2021.1306

Ejemplares similares